Skip to main content
Close up of a hand using a tablet

Latest News

IAB Membership Cycle Applications Being Accepted

January 12, 2024

Canadian Institutes of Health Research (CIHR)

The Canadian Institutes of Health Research (CIHR) is Canada’s federal funding agency for health research. Composed of 13 Institutes, they collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system.

Institute Advisory Boards (IABs)

Each of CIHR’s 13 Institute Advisory Boards advises on Institute-specific issues and cross-Institute initiatives. Composed of a diverse group of national and international representatives of the public, private and non-profit sectors, including the research community and health practitioners, Institute Advisory Boards (IABs) act in an advisory capacity to the Scientific Directors of the Institutes with respect to the full range of Institute activities. These activities include deliberations on Institute health research priorities and strategies and implementation plans for engaging the broader research community. The number of members on an IAB is between eight and 14.

Institute Advisory Board Member Application and Guidelines

Applications for the 2024 IAB Membership Cycle are currently being accepted. The deadline to apply to the 2024 Membership Cycle is April 25, 2024.

CIHR’s institutes bring together all partners in the research process – the people who fund research, those who carry it out and those who use its results – to share ideas and focus on what Canadians need: good health and the means to prevent disease and fight it when it happens. Each institute supports a broad spectrum of research in its topic areas and, in consultation with its stakeholders, sets priorities for research in those areas.

The number of members on an IAB is between 8 and 14. Selection criteria and composition of the IABs is available under the IAB Selection Criteria. Consult the CIHR Institute web pages to review their specific areas of focus.

For more information and to apply to be an IAB member click here


OC MAKES THE NEWS – RECENT ITEMS

DENOZA® is now available in Canada

September 25, 2026

Latest News DENOZA® (denosumab injection), a biosimilar from Apotex, is now available in Canada September 25, 2026 PrDENOZA® is indicated for the treatment of postmenopausal osteoporosis, and to increase bone […]

Healthcare Professional Educational Events

August 19, 2026

Healthcare Professional Educational Events August 19, 2026 View the following information for two events for the healthcare professional: Canadian Symposia on Rare Bone Diseases 2026 ISCD Quality Bone Densitometry: for […]

Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones

July 7, 2026

Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]

© Osteoporosis Canada, 2026
Charitable Registration No. 89551 0931 RR 0001